1 |
Mocroft, A., Youle, M., Phillips, A. N., Halai, R., Easterbrook, P., Johnson, M. A. and Gazzard, B., The incidence of AIDSdefining illnesses in 4883 patients with human immunode-ficiency virus infection. Arch. Intern. Med., 158, 491-497 (1998)
DOI
ScienceOn
|
2 |
Murphy, R. L., Brun, S., and King, M., Lopinavir/ritonavir (Kaletra) in antiretroviral naïve HIV+ patients: 4 year followup [abstract H-165]. 42nd Interscience on Conference on Antimicrobial Agents and Chemotherapy (San Diego). (2002)
|
3 |
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., and Miller, A. H., Paroxetine for the Prevention of Depression Induced by High-Dose Interferon Alfa. N. Engl. J. Med., 344, 961-966 (2001)
DOI
ScienceOn
|
4 |
Nduati, R., Grace, J., Mbori-Ngacha, D., Richardson, B., Overbaugh, J., Mwatha, A., Ndinya-Achola, J., Bwayo, J., Onyango, F. E., Hughes, J., and Kreiss, J., Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomised clinical trial. JAMA., 283, 1167-1174 (2000)
DOI
ScienceOn
|
5 |
Nottermans, D. W., Pakker, N. G., Hamann, D., Foudraine, N. A., Kauffmann, R. H., Meenhorst, P. L., Goudsmit, J., Roos, M. T. L., Schellekens, P. T. A., Miedema, F., and Danner, S. A., Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J. Infect. Dis., 180, 1050-1056 (1999)
DOI
ScienceOn
|
6 |
Department of Health and Human Services. Panel on clinical practices for the treatment of HIV infection-Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. (2005)
|
7 |
Perrillo, R. P., Regenstein, F. G., and Roodman, S. T., Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann. Intern. Med., 105, 382-3 (1986)
DOI
ScienceOn
|
8 |
Picard, V., Angelini, E., Maillard, A., Race, E., Clavel, F., Chene, G., Ferchal, F., and Molina, J. M., Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J. Infect. Dis., 184, 781-784 (2001)
DOI
ScienceOn
|
9 |
Piroth, L., Duong, M., Quantin, C., Abrahamowicz, M., Michardiere, R., Aho, L. S., Grappin, M., Buisson, M., Waldner, A., Portier, H., and Chavanet, P., Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIVinfected patients? AIDS., 12, 381-388 (1998)
DOI
ScienceOn
|
10 |
Piwoz, E. G., Ross, J., and Humphrey, J., Human immunodeficiency virus transmission during breastfeeding: knowledge, gaps, and challenges for the future. Adv. Exp. Med. Biol., 554, 195-210 (2004)
|
11 |
Public Health Service Task Force. Recommendations for Use of Antiretroviral drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. MMWR., 47 (RR-2) 1-55 (2005)
|
12 |
Rana, K. Z. and Dudley, M. N., Clinical pharmacokinetics of stavudine. Clin. Pharmacokinet., 33, 276-284 (1997)
DOI
ScienceOn
|
13 |
Rodriguez, M., Berenguer, J., Rodriguez-Rosado, R., Carbo, J., Asensi, V., and Soriano, V., Hepatocellular carcinoma in HIVinfected patients with chronic hepatitis C. Am. J. Gastroenterol., 96, 179-183 (2001)
DOI
|
14 |
Shire, N. J. and Sherman, K. E., Management of HBV/HIV coinfected patients. Seminars in Liver Disease, 25 (Suppl 1), 48-57 (2005)
|
15 |
Spengler, U., Lichterfeld, M., and Rockstroh, J. K., Antiretroviral drug toxicity -- a challenge for the hepatologist? J. Hepatol. 36, 283-294 (2002)
DOI
ScienceOn
|
16 |
Van Ameijden, E. J., van den Hoek, J. A., Mientjes, G. H., and Coutinho, R. A., A longitudinal study on the incidence and transmission patters on HIV, HBV and HCV infection among drug users in Amsterdam. Eur. J. Epidemiol., 9, 255-262 (1993)
DOI
|
17 |
Sterling, T. R., Chaisson, R. E., and Moore, R. D., Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity. Clin. Infect. Dis., 36, 812-815 (2003)
DOI
ScienceOn
|
18 |
Tenney, D. J., Levine, S. M., Rose, R. E., Walsh, A. W., Weinheimer, S. P., Discoto, L., Plym, M., Pokornowski, K., Yu, C. F., Angus, P., Ayres, A., Bartholomeusz, A., Sievert, W., Thompson, G., Warner, N., Locarnini, S., and Colonno, R., J. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents. Chemother., 48, 3498-5307 (2004)
DOI
ScienceOn
|
19 |
Thorne, C. and Newell, M. L., Treatment options for the prevention of mother-to-child transmission of HIV. Cur. Opin. Invest. Drugs., 6, 804-811 (2005)
|
20 |
Van Gemen, B., Van Beuningen, R., and Nabbe, A., A one tube quantitative HIV-1 RNA NASBS nucleic acid amplification assay using electrochemiluminescent (ECL) labeled probes. J. Virolog. Method., 49, 157-168 (1994)
DOI
ScienceOn
|
21 |
White, K. L., Margot, N. A., Ly, J. K., Chen, J. M., Ray, A. S., Pavelko, M., Wang, R., McDermott, M., Swaminathan, S., and Miller, M. D., A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS., 19, 1751-1760 (2005)
DOI
ScienceOn
|
22 |
Winnock, M., Salmon-Céron, D., Dabis, F., and Chêne, G., Interaction between HIV-1 and HCV infections: towards a new entity? J. Antimicrob. Chemother., 53, 936-946 (2004)
DOI
ScienceOn
|
23 |
Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A., and Koopmans, P. P., Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS., 12, 1735-1744 (1998)
DOI
ScienceOn
|
24 |
Wolbach, J. and Capoccia, K., A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection. Nurse Practitioner., 24, 81-92 (1999)
DOI
|
25 |
Baxter, J. D., Mayers, D. L., Wentworth, D. N., Neaton, J. D., Hoover, M. L., Winters, M. A., Mannheimer, S. B., Thompson, M. A., Abrams, D. I., Brizz, B. J., Ioannidis, J. P., and Merigan, T. C., A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS., 14, F83-93 (2000)
DOI
ScienceOn
|
26 |
Benhamou, Y., Bochet, M., Thibault, V., Calvez, V., Fievet, M. H., Vig, P., Gibbs, C. S., Brosgart, C., Fry, J., Namini, H., Katlama, C., and Poynard T., Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudineresistant hepatitis B virus: an open-label pilot study. Lancet., 358, 718-723 (2001)
DOI
ScienceOn
|
27 |
Benhamou, Y., Tubiana, R., and Thibault, V., Tenofovir disoproxil fumarate in patients with HIV and lamivudineresistant hepatitis B virus. N. Engl. J. Med., 348, 177-178 (2003)
DOI
ScienceOn
|
28 |
Bozzette, S. A., Ake, C. F., Tam, H. K., Chang, S. W., and Louis, T. A., Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med., 348, 702-710 (2003)
DOI
ScienceOn
|
29 |
Bristol-Myers Squibb. Important drug warning: January 5, 2001. Rockville, Md.: Food and Drug Administration, 2001. (Accessed February 15 2006, at http://www.fda.gov/medwatch/safety/ 2001/zerit&videx_letter.htm
|
30 |
Brunelle, M. N., Jacquard, A. C., Pichoud, C., Durantel, D., Carrouee-Durantel, S., Villeneuve, J. P., Trepo, C., and Zoulim, F., Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology, 41, 1391-1398 (2005)
DOI
ScienceOn
|
31 |
Campo, R. E., Lalanne, R., Tanner, T. J., Jayaweera, D. T., Rodriguez, A. E., Fontaine, L., and Kolber, M. A., Lopinavir/ ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS., 19, 447-449 (2005)
DOI
ScienceOn
|
32 |
Cervia, J. S. and Smith, M. A., Enfuvirtide (T-20): A novel human immunodeficiency virus type 1 fusion inhibitor. Clin. Infect. Dis., 37, 1102-1106 (2003)
DOI
ScienceOn
|
33 |
Chamot, E., Hirschel, B., Wintsch, J., Robert, C. F., Gabriel, V., Deglon, J. J., Yerly, S., and Perrin, L., Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. AIDS., 4, 1275-1277 (1990)
DOI
ScienceOn
|
34 |
Cooper, E. R., Charurat, M., Mofenson, L., Hanson, I. C., Pitt, J., Diaz, C., Hayani, K., Handelsman, E., Smeriglio, V., Hoff, R., Blattner, W., and the Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr., 29, 484-494 (2002)
|
35 |
Demeter, L. M. and Reichman, R. C., Delavirdine, p 97-105. In Dolin R, Masur H, and Saag MS (ed), AIDS Therapy. Churchill Livingstone, Philadelphia. (1999)
|
36 |
Dorenbaum, A., Cunningham, C. K., Gelber, R. D., Culnane, M., Mofenson, L., Britto, P., Rekacewicz, C., Newell, M. L., Delfraissy, J. F., Cunningham-Schrader, B., Mirochnick, M., Sullivan, J. L., and the International PACTG 316 Team. Twodose-- intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial. JAMA., 288, 189-198 (2002)
DOI
ScienceOn
|
37 |
Eskild, A., Magnus, P., Petersen, G., Sohlberg, C., Jensen, F., Kittelsen, P., and Skaug, K., Hepatitis B antibodies in HIVinfected homosexual men are associated with more rapid progression to AIDS. AIDS., 6, 571-574 (1992)
DOI
ScienceOn
|
38 |
Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L., and Lamarre, D., Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol., 70, 3763-3769 (1996)
|
39 |
Dube, M. P. and Sattler, F. R., Metabolic complications of antiretroviral therapies. AIDS Clin. Care., 10, 41-44 (1998)
|
40 |
Durant, J., Clevenbergh, P., Halfon, P., Delgiudice, P., Porsin, S., Simonet, P., Montagne, N., Boucher, C. A., Schapiro, J. M., and Dellamonica, P., Drug-resistance genotyping in HIV- 1 therapy: the VIRADAPT randomised controlled trial. Lancet., 353, 2195-2199 (1999)
DOI
ScienceOn
|
41 |
Fischl, M. A., Zidovudine, p. 17-31. In Dolin R, Masur H, and Saag MS (ed),AIDS Therapy. Churchill Livingstone, Philadelphia. (1999)
|
42 |
Flexner, C., HIV-protease inhibitors. N. Engl. J. Med., 338, 1281-1292 (1998)
DOI
ScienceOn
|
43 |
Foster, R. H. and Faulds, D., Abacavir. Drugs, 55, 729-736 (1998)
DOI
|
44 |
Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., Toole, J. J., and Cheng, A. K., Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med., 354, 251- 260 (2006)
DOI
ScienceOn
|
45 |
Gerard, Y., Maulin, L., Yazdanpanah, Y., De La Tribonniere, X., Amiel, C., Maurage, C. A., Robin, S., Sablonniere, B., Dhennain, C., and Mouton, Y., Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS., 14, 2723-2730 (2000)
DOI
ScienceOn
|
46 |
Hilts, A. E. and Fish, D. N., Dosage adjustment of antiretroviral agents in patients with organ dysfunction. Am. J. Health-Syst. Pharm., 55, 2528-2533 (1998)
|
47 |
Greub, G., Ledergerber, B., Battegay, M., Grob, P., Perrin, L., Furrer, H., Burgisser, P., Erb, P., Boggian, K., Piffaretti, J. C., Hirschel, B., Janin, P., Francioli, P., Flepp, M., and Telenti A., Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet., 356, 1800-1805 (2000)
DOI
ScienceOn
|
48 |
Hanna, G. J. and Hirsch, M. S., New Drugs in Development p. 263-272 In Dolin R, Masur H, and Saag MS (ed), AIDS Therapy. Churchill Livingstone, Philadelphia. (2003)
|
49 |
Haubrich, R. H., Kemper, C. A., Hellmann, N. S., Keiser, P. H., Witt, M. D., Tilles, J. G., Forthal, D. N., Leedom, J., Leibowitz, M., McCutchan, J. A., Richman, D. D., and the California Collaborative Treatment Group. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS., 19, 295-302 (2005)
|
50 |
Imhof, A., Ledergerber, B., Gunthard, H. F., Haupts, S., and Weber, R., Swiss HIV Cohort Study. Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? Clin. Infect. Dis., 41, 721-728 (2005)
DOI
ScienceOn
|
51 |
Iversen, A. K., Shafer, R. W., Wehrly, K., Winters, M. A., Mullins, J. I., Chesebro, B., and Merigan, T. C., Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol., 70, 1086-1090 (1996)
|
52 |
Jarvis, B. and Faulds, D., Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs., 56, 147-167 (1998)
DOI
ScienceOn
|
53 |
Joint United Nations Programme on HIV/AIDS (UNAIDS), and World Health Organization (WHO). Global Summary of the AIDS Epidemic. AIDS epidemic update: December 2005, 1-2 (2005)
|
54 |
Kurowski, M., Kaeser, B., Sawyer, A., Popescu, M., and Mrozikiewicz, A., Low-dose ritonavir moderately enhances nelfinavir exposure. Clin. Pharmacol. Ther., 72, 123-132 (2002)
DOI
ScienceOn
|
55 |
Katner, H. P., Paar, D. P., Nadler, J. P., Jensen, E. H., Wilson, H. M., Finn, T. S., Petruschke, R. A., and Zeldin, R. K., Openlabel study of a twice-daily indinavir 800-mg/ritonavir 200 mg regimen in HIV-infected adults failing a protease inhibitor regimen. J. AIDS., 483-487 (2002)
|
56 |
Karrer, U., Ledergerber, B., Furrer, H., Elzi, L,. Battegay, M., Cavassini, M., Gayet-Ageron, A., Hirschel, B., Schmid, P., Russotti, M., Weber, R., and Speck, R. F., Swiss HIV Cohort Study. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS., 19, 1987-1994 (2005)
DOI
ScienceOn
|
57 |
Kearney, B. P., Flaherty, J. F., and Shah, J., Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharm., 43, 595-612 (2004)
DOI
ScienceOn
|
58 |
Landau, A., Batisse, D., Piketty, C., Jian, R., and Kazatchkin, M., Lack of interference between ribavirin and nucleoside analogues in HIV/HCV coinfected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. AIDS., 14, 1857-1858 (2000)
DOI
ScienceOn
|
59 |
Larder, B. A., and Kemp, S. D., Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science, 246, 1155-1158 (1989)
DOI
|
60 |
Larder, B. A., Kemp, S. D., and Harrigan, P. R., Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science., 269, 696-699 (1995)
DOI
|
61 |
Malik, A., Abraham, P., and Malik, N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment- -case report and review of literature. J. Infect. 51, E61-65 (2005)
DOI
ScienceOn
|
62 |
Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arasteh, K., Nelson, M., Katlama, C., Stellbrink, H. J., Delfraissy, J. F., Lange, J., Huson, L., DeMasi, R., Wat, C., Delehanty, J., Drobnes, C., and Salgo, M., TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med., 348, 2186-2195 (2003)
DOI
ScienceOn
|
63 |
Le Tiec, C., Barrail, A., Goujard, C., and Taburet, A. M., Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet., 44, 1035-50 (2005)
DOI
|
64 |
Maitland, D., Moyle, G., Hand, J., Mandalia, S., Boffito, M., Nelson, M., and Gazzard, B., Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS. 19,1183-1188 (2005)
DOI
ScienceOn
|
65 |
Martinez, E., Arnaiz, J. A., Podzamczer, D., Dalmau, D., Ribera, E., Domingo, P., Knobel, H., Riera, M., Pedrol, E., Force, L., Llibre, J. M., Segura, F., Richart, C., Cortes, C., Javaloyas, M., Aranda, M., Cruceta, A., de Lazzari, E., and Gatell, J. M., Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N. Engl. J. Med., 349, 1036-1046 (2003)
DOI
ScienceOn
|
66 |
Mock, P. A., Shaffer, N., Bhadrakom, C., Siriwasin, W., Chotpitayasunondh, T., Chearskul, S., Young, N. L., Roongpisuthipong, A., Chinayon, P., Kalish, M. L., Parekh, B., and Mastro, T. D., Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. AIDS., 13, 407-414 (1999)
DOI
ScienceOn
|
67 |
CDC. Updated US Public health service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR, 54, RR-9 (2005)
|
68 |
Lauer, G. M. and Walker, B. D., Hepatitis C Virus Infection. N. Engl. J. Med., 345, 41-52 (2001)
DOI
ScienceOn
|
69 |
Moyle, G., Pozniak, A., Opravil, M., Clumeck, N., DelFraissy, J. - F., Johnson, M., Pelgrom, J., Reynes, J., Vittecoq, D., DeLora, P., Salgo, M., and Duff, F., The SPICE study: 48- week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. J. AIDS., 23, 128-137 (2000)
|
70 |
Brook, M. G., McDonald, J. A., Karayiannis, P., Caruso, L., Forster, G., Harris, J. R., and Thomas, H. C., Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut., 30, 1116-1122 (1989)
DOI
|
71 |
The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS., 13, 1377-1385 (1999)
DOI
ScienceOn
|
72 |
Havlir, D. V., Marschner, I. C., Hirsch, M. S., Collier, A. C., Tebas, P., Bassett, R. L., Ioannidis, J. P. A., Holohan, M. K., Leavitt, R., Boone, G., Richman, D. D., Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N. Engl. J. Med., 339, 1261-1268 (1998)
DOI
ScienceOn
|
73 |
Hirsch, M. S., Azidothymidine. J. Inf. Dis., 157, 427-430 (1998)
|
74 |
Aarnoutse, R. E., Grintjes, K. J., Telgt, D. S., Stek, M., Hugen, P. W., Reiss, P., Koopmans, P. P., Hekster, Y.A., and Burger, D. M., The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin. Pharmacol. Ther., 71, 57-67 (2002)
DOI
ScienceOn
|
75 |
Di Martino, V., Thevenot, T., Colin, J. F., Boyer, N., Martinot, M., Degos, F., Coulaud, J. P., Vilde, J. L., Vachon, F., Degott, C., Valla, D., and Marcellin, P., Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology, 123, 1812-1822 (2002)
DOI
ScienceOn
|
76 |
Gallant, J. E., Rodriguez, A. E., Weinberg, W. G., Young, B., Berger, D. S., Lim, M. L., Liao, Q., Ross, L,. Johnson, J., and Shaefer, M. S., ESS30009 Study. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis., 192, 1921-1930 (2005)
DOI
ScienceOn
|
77 |
McDowell, J. A., Chittick, G. E., Ravitch, J. R., Polk, R. E., Kerkering, T. M., and Stein, D. S., Pharmacokinetics of abacavir, a human immunodeficiency virus type 1 reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents. Chemother., 43, 2855-2861 (1999)
|
78 |
Public Health Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR., 47(RR-2) 1-30 (1998)
|
79 |
O'Brien, W. A., Hartigan, P. M., Daar, E. S., Simberkoff, M. S., and Hamilton, J. D., Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann. Intern. Med., 126, 939-945 (1997)
DOI
ScienceOn
|
80 |
Pomerantz, R. J., How HIV Resists Eradication. Hosp. Pract., 87-101 (1998)
|
81 |
Samuel, R. and Suh, B., Antiretroviral therapy 2000. Arch. Pharm. Res., 23, 425-437 (2000)
DOI
ScienceOn
|
82 |
Soriano, V., Sulkowski, M., Bergin, C., Hatzakis, A., Cacoub, P., Katlama, C., Cargnel, A., Mauss, S., Dieterich, D., Moreno, S., Ferrari, C., Poynard, T., and Rockstroh, J., Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS., 16, 813- 828 (2002)
DOI
ScienceOn
|
83 |
Sulkowski, M. S., Moore, R. D., Mehta, S. H., Chaisson, R. E., and Thomas, D. L., Hepatitis C and progression of HIV disease. JAMA., 288, 199-206 (2002)
DOI
ScienceOn
|
84 |
Vlahov, D., Graham, N., Hoover, D., Flynn, C., Bartlett, J. G., Margolick, J. B., Lyles, C. M., Nelson, K., E., Smith, D., Holmberg, S., and Farzadegan, H., Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users- plasma viral load and CD4+ cell count. JAMA., 279, 35-40 (1998)
DOI
ScienceOn
|
85 |
Ying, C., De Clercq, E., Nicholson, W., Furman, P., and Neyts, J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J. Viral. Hepat., 7, 161-165 (2000)
DOI
ScienceOn
|
86 |
Katlama, C. and Havlir, D. V., Newer nucleosides: lamivudine and stavudine. AIDS., 10, (supple A), S135-S143 (1996)
DOI
ScienceOn
|
87 |
Young, B., Fischl, M. A., Wilson, H. M., Finn, T. S., Jensen, E. H., DiNubile, M. J., and Zeldin, R. K., Open-label study of a twice-daily indinavir 800-mg/ritonavir 100 mg regimen in protease inhibitor-naive HIV-infected adults. JAIDS., 31, 478- 482 (2002)
DOI
ScienceOn
|
88 |
Bartlett, J. A., Zalcitabine, p. 49-59. In Dolin R, Masur H, and Saag MS (ed), AIDS Therapy. Churchill Livingstone, Philadelphia, (1999)
|
89 |
Clavel, F. and Hance, A. J., HIV Drug Resistance. N. Engl. J. Med., 350, 1023-1035 (2004)
DOI
ScienceOn
|
90 |
Hoffman-LaRoche, Inc. Roferon-A Package Insert. (2001)
|
91 |
Marcellin, P., Asselah, T., and Boyer, N., Treatment of chronic hepatitis B. J. Viral. Hepatit., 12, 333-345 (2005)
DOI
ScienceOn
|
92 |
Menzo, S., Castagna, A., Monachetti, A., Hasson, H., Danise, A., Carini, E., Bagnarelli, P., Lazzarin, A., and Clementi, M., Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob. Agents. Chemother., 48, 3253-3259 (2004)
DOI
ScienceOn
|
93 |
Núñez, M., Puoti, M., Camino, N., and Soriano, V., Treatment of chronic hepatitis B in the human immunodeficiency virusinfected patient: present and future. Clin. Infect. Dis., 37, 1678-1685 (2003)
DOI
ScienceOn
|
94 |
Perry, C. M. and Noble, S., Didanosine: An updated review of its use in HIV infection. Drugs, 58, 1099-1135 (1999)
DOI
ScienceOn
|
95 |
Resch, W., Parkin, N., Stuelke, E. L., Watkins, T., and Swanstrom, R., A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. P. Natl. Acad. Sci. U.S.A., 98, 176-181 (2001)
|
96 |
CDC. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. Recommendations from the US Department of Health and Human Services. MMWR, 54, RR- 2 (2005)
|
97 |
Rockstroh, J. K., Mocroft, A., Soriano, V., Tural, C., Losso, M. H., Horban, A., Kirk, O., Phillips, A., Ledergerber, B., Lundgren, J., and the EuroSIDA Study Group. Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy. J. Infect. Dis., 192, 992-1002 (2005)
DOI
ScienceOn
|
98 |
Saag, M. S., Emtricitabine, a new antiretroviral agent with activity against HIV and Hepatitis B Virus. Clin. Infect. Dis., 42, 126-131 (2006)
DOI
ScienceOn
|
99 |
Soriano, V., Martin-Carbonero, L., Maida, I., Garcia-Samaniego, J., and Núñez, M., New paradigms in the management of HIV and hepatitis C virus coinfection. Curr. Opin. Infect. Dis., 18, 550-560 (2005)
DOI
ScienceOn
|
100 |
US Department of Health and Human Services, HIV/AIDS Treatment and Information Service. Safety and toxicity of individual antiretroviral agents in pregnancy, May 17, 2002. In: Guidelines for the use of antiretroviral agents in HIVinfected adults and adolescents. MMWR., 51(RR7), 1-64 (2002)
|
101 |
Cameron, D. W., Japour, A. J., Xu, Y., Hsu, A., Mellors, J., Farthing, C., Cohen, C., Poretz, D., Markowitz, M., Follansbee, S., Angel, J. B., McMahon, D., Ho, D., Devanarayan, V., Rode, R., Salgo, M., Kempf, D. J., Granneman, R., Leonard, J. M., and Sun, E., Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS., 13, 213-224 (1999)
DOI
ScienceOn
|
102 |
Gerberding, J. L., Prophylaxis for occupational exposure to HIV. Ann. Intern. Med., 125, 497-501 (1996)
DOI
ScienceOn
|
103 |
Lisziewicz, J., Rosenberg, E., Lieberman, J., Jessen, H., Lopalco, L., Siliciano, R., Walker, B., and Lori, F., Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med., 340,1683-1684 (1999)
DOI
ScienceOn
|
104 |
Pesce, A., Taillan, B., and Rosenthal, E., Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet., 341, 1597 (1993)
DOI
|
105 |
Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S. A., Mulder, J., Loveday, C., and Christopherson, C., Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drugresistant virus populations in persons treated with lamivudine (3TC). J. Infect Dis., 171, 1411-1419 (1995)
DOI
ScienceOn
|
106 |
Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., Phair, J. P., and Rinaldo, C. R., Plasma viral load and CD4+ Lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med., 126:946-954 (1997)
DOI
ScienceOn
|
107 |
di Martino, V., Lunel, F., Cadranel, J. F., Hoang, C., Parlier, Y., Le Charpentier, Y., and Opolon, P., Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J. Vir. Hepat., 3, 253-260 (1996)
DOI
ScienceOn
|
108 |
Kakuda, T. and Brinkman, K., Mitochondrial toxic effects of ribavirin. Lancet., 357, 1802-1803 (2001)
|
109 |
Kuhn, L., Abrams, E. J., Matheson, P. B., Thomas, P. A., Lambert, G., Bamji, M., Greenberg, B., Steketee, R. W., Thea, D. M., for the New York City Perinatal HIV Transmission Collaborative Study Group. Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. AIDS., 11, 429-435 (1997)
DOI
ScienceOn
|
110 |
Núñez, M., Maida, I., Berdún, M., and Soriano, V., Efficacy and safety of pegylated interferon a-2a plus ribavirin for the treatment of hepatitis C in HIV-coinfected patients: the PRESCO trial. In: 44th ICAAC, Abstract V-1148 (2004)
|
111 |
Solomon, R. E., VanRaden, M., Kaslow, R. A., Lyter, D., Visscher, B., Farzadegan, H., and Phair, J., Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection. Am. J. Public Health., 80, 1475-1478 (1990)
DOI
|
112 |
Weinheimer, S., Discotto, L., Friborg, J., Yang, H., and Colonno, R., Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob. Agent. Chemother., 49, 3816-3824 (2005)
DOI
ScienceOn
|
113 |
Gerstoft, J., Mallolas, J., and Lundgren, J., A randomized trial comparing continued indinavir vs. switching to indinavir plus ritonavir in HIV patients having suppressed viral load with indinavir plus two nucleoside analogue reverse transcriptase inhibitors: the best study [abstract O-8]. In: 8th European Conference on Clinical aspects and Treatment of HIV Infection. Athens (2001)
|
114 |
Yerly, S., Perneger, T. V., Hirschel, B., Dubuis, O., Matter, L., Malinverni, R., Furrer, H., and Perrin, L., A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. Arch. Intern. Med., 158, 247- 252 (1998)
DOI
ScienceOn
|
115 |
Arvieux, C. and Tribut, O., Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs, 65, 633-659 (2005)
DOI
ScienceOn
|
116 |
Bodsworth, N. J., Cooper, D. A., and Donovan B., The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J. Infect. Dis., 163, 1138-1140 (1991)
DOI
ScienceOn
|
117 |
Buti, M. and Esteban, R. Drugs in Development for Hepatitis B. Drugs., 65, 1451-1460 (2005)
DOI
ScienceOn
|
118 |
Carr, A., Samaras, K. Chisholm, D. J., and Cooper, D. A., Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet., 352, 1881-1883 (1998)
|
119 |
Grinspoon, S. and Carr, A., Cardiovascular risk and body-fat abnormalities in HIV infected adults. N. Engl. J. Med., 352, 48-62 (2005)
DOI
ScienceOn
|
120 |
Hecht, F. M., Grant, R. M., Petropoulos, C. J., Dillon, B., Chesney, M. A., Tian, H., Hellmann, N. S., Bandrapalli, N. I., Digilio, L., Branson, B., and Kahn, J. O., Brief Report: Sexual Transmission of an HIV-1 Variant Resistant to Multiple Reverse-Transcriptase and Protease Inhibitors N. Engl. J. Med., 339, 307-311 (1998)
DOI
ScienceOn
|
121 |
Kempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., McDonald, E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., Sun, E., Pizzuti, D., Plattner, J. J., Norbeck, D. W., and Leonard, J. M., Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents. Chemother., 41, 654-660 (1997)
|
122 |
Kosalaraksa, P., Kavlick, M. F., Maroun, V., Le R., and Mitsuya, H., Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J. Virol., 73, 5356-5363 (1999)
|
123 |
Sabin, C., Staszewski, S., Phillips, A. Rabenau, H., Cozzi Lepri, A., Weidman, E., and Miller, V., Discordant immunological and virological responses to HAART. Abstract 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, U.S.A. (2000)
|
124 |
Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-Garcia, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., Sette, H. Jr., Passe, S., De Pamphilis, J., Duff, F., Schrenk, U. M., and Dieterich, D. T., for the APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med., 351, 438-450 (2004)
DOI
ScienceOn
|
125 |
Preston, D. B., Poiesz, B. J., and Loeb, L. A., Fidelity of HIV-1 reverse transcriptase. Science, 242, 1168-1171 (1998)
|
126 |
Collier, A. C., Coombs, R. W., Schoenffeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., Friedman, H. M., Merigan, T. C., Reichman, R. C., Hooper, C., and Corey, L., Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med., 334, 1011-1017 (1996)
DOI
ScienceOn
|
127 |
Connor, E. M., Sperling, R. S., Gelber, R., and Kiselev, P., Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med., 331, 1173-1180 (1994)
DOI
ScienceOn
|
128 |
Dube, M. P., Stein, J. H., Aberg, J. A., Fichtenbaum, C. J., Gerber, J. G., Tashima, K. T., Henry, W. K., Currier, J. S., Sprecher, D., and Glesby, M. J., Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis., 37, 613-627 (2003)
DOI
ScienceOn
|
129 |
Hoff, J., Bani-Sadr, F., Gassin, M., and Raffi, F., Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin. Infect. Dis., 32, 963- 969 (2001)
DOI
ScienceOn
|
130 |
Pachl, C., Todd, J. A., and Kern, D. G., Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J. AIDS., 8, 446-454 (1995)
|
131 |
Rodriguez-French, A., Boghossian, J., Gray, G. E,. Nadler, J. P., Quinones, A. R., Sepulveda, G. E., Millard, J. M., and Wannamaker, P. G., The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J. AIDS., 35, 22-32 (2004)
DOI
ScienceOn
|
132 |
Ristig, M. B., Crippin, J., Aberg, J. A., Powderly, W. G., Lisker- Melman, M., Kessels, L., and Tebas, P., Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J. Infect. Dis., 186, 1844-1847 (2002)
DOI
ScienceOn
|
133 |
Friis-Moller, N., Sabin, C. A., Weber, R., d'Arminio Monforte, A., El-Sadr, W. M., Reiss, P., Thiebaut, R., Morfeldt, L., De Wit, S., Pradier, C., Calvo, G., Law, M. G., Kirk, O., Phillips, A. N., and Lundgren, J. D., Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med., 349, 1993-2003 (2003)
DOI
ScienceOn
|
134 |
Dragsted, U. B., Gerstoft, J., Pedersen, C., Peters, B., Duran, A., Obel, N., Castagna, A., Cahn, P., Clumeck, N., Bruun, J. N., Benetucci, J., Hill, A., Cassetti, I., Vernazza, P., Youle, M., Fox, Z., Lundgren, J. D., and the MaxCmin1 Trial Group. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1- infected patients: the MaxCmin1 Trial. J. Infect. Dis., 188, 635-642 (2003)
DOI
ScienceOn
|
135 |
Dube, M. P., Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin. Infect. Dis., 31, 1467-1475 (2000)
DOI
ScienceOn
|
136 |
Feng, J. Y., Myrick, F. T., Margot, N. A., Mulamba, G. B., Rimsky, L., Borroto-Esoda, K., Selmi, B., and Canard, B., Virologic and enzymatic studies revealing the mechanism of K65Rand Q151m-associated HIV-1 drug resistance towards emtricitabine and lamivudine. Nucleos. Nucleot. Nucl., 25, 89-107 (2006)
DOI
ScienceOn
|
137 |
Katlama, C., Berger, D., Bellos, N., Grinsztejn, B., Haubrich, R., Wilkin, T., Monlina, J. M., Steinhart, C., Pedro, R., de Bethune, M. P., De Meyer, S., Hoetelmans, R., Parys, W., Vangeneuden, T., and Lefebvre, E., Efficacy of TMC114/r in 3 class experienced patients with limited treatment options: 24 week planned interim analysis of 2 96 week multinational dosefinding trials. Abstract 164LB Conference on Retroviruses and Opportunistic Infections, Boston, MA. U.S.A. (2005)
|
138 |
Martin, A., Smith, D. E., Carr, A., Ringland, C., Amin, J., Emery, S., Hoy, J., Workman, C., Doong, N., Freund, J., and Cooper, D. A., Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS., 18, 1029-1036 (2004)
DOI
ScienceOn
|
139 |
Veldkamp, A. I., van Heeswijk, R. P., Mulder, J. W., Meenhorst, P. L., Schreij, G., van der Geest, S., Lange, J. M., Beijnen, J. H., and Hoetelmans, R. M., Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1- infected individuals. J. AIDS., 27, 344-349 (2001)
|
140 |
Soto, B., Sanchez-Quijano, A., Rodrigo, L., del Olmo, J. A., Garcia-Bengoechea, M., Hernandez-Quero, J., Rey, C., Abad, M. A., Rodriguez, M., Sales Gilabert, M., Gonzalez F., Miron, P., Caruz, A., Relimpio, F., Torronteras, R., Leal, M., and Lissen, E. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol., 26, 1-5 (1997)
|
141 |
Detels, R., Munoz, A., McFarlane, G., Kingsley, L. A., Margolick, J. B., Giorgi, J., Schrager, L. K., and Phair, J. P., Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA., 280, 1497- 1503 (1998)
DOI
ScienceOn
|
142 |
Adkins, J. C. and Noble, S., Efavirenz. Drugs, 56, 1055-1064 (1998)
DOI
|
143 |
Darby, S. C., Ewart, D. W., Giangrande, P. L., Spooner, R. J., Rizza, C. R., Dusheiko, G. M., Lee, C. A., Ludlam, C. A., and Preston, F. E., Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet., 350, 1425-1431 (1997)
DOI
ScienceOn
|
144 |
Deeks, S. G., Wrin, T., Liegler, T., Hoh, R., Hayden, M., Barbour, J. D., Hellmann, N. S., Petropoulos, C. J., McCune, J. M., Hellerstein, M. K., and Grant, R. M., Virologic and immunologic consequences of discontinuing combination antiretroviraldrug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med., 344, 472-480 (2001)
DOI
ScienceOn
|
145 |
Keswani, S. C., Pardo, C. A., Cherry, C. L., Hoke, A. and McArthur, J. C., HIV-associated sensory neuropathies. AIDS., 16, 2105-2117 (2002)
DOI
|
146 |
Knudtson, E., Para, M., Boswell, H., and Fan-Havard, P., Drug Rash with Eosinophilia and Systemic Symptoms Syndrome and Renal Toxicity with a Nevirapine-Containing Regimen in a Pregnant Patient with Human Immunodeficiency Virus. Obstet. Gynecol., 101, 1094-1097 (2003)
DOI
ScienceOn
|
147 |
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Jonas, L., Meibohm, A., Holder, D., Schleif, W. A., Condra, J. H., Emini, E. A., Isaacs, R., Chodakewitz, J. A., and Richman, D. D., Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV- 1 infection. JAMA., 280, 35-41 (1998)
DOI
ScienceOn
|
148 |
Mofenson, L. M. and the U.S. Public Health Service Task Force Recommendations for Use--of Antiretroviral Drugs in Pregnant HIV-1--Infected Women for Maternal Health and Interventions To Reduce Perinatal HIV-1 Transmission in the United States. MMWR., 51 (RR18), 1-38 (2002)
|
149 |
Sarisky, R. T., Non-nucleoside inhibitors of the HCV polymerase. J. Anitmicrob. Chemother., 54, 14-16 (2004)
DOI
ScienceOn
|
150 |
Folks, T. M. and Hart, C. E., The life cycle of human immunodeficiency virus type 1, p 29-44. In DeVita Jr VT, Hellman S and Rosenberg SA (ed), AIDS. Lippincott-Raven Publishers, Philadelphia. (1997)
|
151 |
Kilby, J. M. and Eron, J. J., Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med., 348, 2228-2238 (2003)
DOI
ScienceOn
|
152 |
Lurie, P., Miller, S., Hecht, F., Chesney, M., and Lo, B., Postexposure prophylaxis after nonoccupational HIV exposure. JAMA., 280, 1769-1773 (1998)
DOI
ScienceOn
|
153 |
Murphy, R. L., Gulick, R. M., DeGruttola, V., D'Aquila, R. T., Eron, J. J., Sommadossi, J. -P., Currier, J. S., Smeaton, L., Frank, I., Caliendo, A. M., Gerber, J. G., Tung, R., and Kuritzkes, D. R., Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J. Infect. Dis., 179, 808-816 (1999)
DOI
ScienceOn
|
154 |
Pialoux, G., Raffi, F., Brun-Vezinet, F., Meiffredy, V., Flandre, P., Gastaut, J. A., Dellamonica, P., Yeni, P., Delfraissy, J. F., and Aboulker, J. P., A randomized trial of three maintenance regiments given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N. Engl. J. Med., 339, 1269-1276 (1998)
DOI
ScienceOn
|
155 |
Japour, A., Lertora, J., Meehan, P. M., Erice, A., Connor, J. D., Griggith, B. P., Clax, P. A., Holden-Wiltse, J., Hussey, S., Walesky, M., Cooney, E., Pollard, R., Timpone, J., McLaren, C., Johanneson, N., Wood, K., Booth, D., Bassiakos, Y., and Crumpacker, C. S., A phase I study on the safety, pharmacokinetics and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease (ACTG 231 protocol). J. AIDS., 13, 235-246 (1996)
과학기술학회마을
|
156 |
Chapman, T. M., Plosker, G. L., and Perry, C. M., Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs., 64, 2101- 2124 (2004)
DOI
|
157 |
den Brinker, M., Wit, F. W., Wertheim-van Dillen, P. M., Jurriaans, S., Weel, J., van Leeuwen, R., Pakker, N. G., Reiss, P., Danner, S. A., Weverling, G. J., and Lange, J. M., Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS., 14, 2895-2902 (2000)
DOI
ScienceOn
|
158 |
Hoofnagle, J. H., and Di Bisceglie, A. M., Drug Therapy: The Treatment of Chronic Viral Hepatitis. N. Engl. J. Med., 336, 347-356 (1997)
DOI
ScienceOn
|
159 |
Konopnicki, D., Mocroft, A., de Wit, S., Antunes, F., Ledergerber, B., Katlama, C., Zilmer, K., Vella, S., Kirk, O., Lundgren, J. D., and the EuroSIDA Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS., 19, 593-601 (2005)
DOI
ScienceOn
|
160 |
Scully, C. and Porter, S., HIV topic update: oro-genital transmission of HIV. Oral Dis., 6, 92-98 (2000)
DOI
ScienceOn
|
161 |
Tuomala, R. E., Shapiro, D. E., Mofenson, L. M., Bryson, Y., Culnane, M., Hughes, M. D., O'Sullivan, M. J., Scott, G., Stek, A. M., Wara, D., and Bulterys, M., Antiretroviral Therapy During Pregnancy and the Risk of an Adverse Outcome. N. Engl. J. Med., 346, 1863-1870 (2002)
DOI
ScienceOn
|
162 |
Hinrichsen, H., Benhamou, Y., Wedemeyer, H., Reiser, M., Sentjens, R. E., Calleja, J. L., Forns, X., Erhardt, A., Cronlein, J., Chaves, R. L., Yong, C. L., Nehmiz, G., and Steinmann, G. G., Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterol., 127, 1347-1355 (2004)
DOI
ScienceOn
|
163 |
Cohen, C. J., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, S., Nadler, J., Verbiest, W., Hertogs, K., Ames, M., Rinehart, A. R., Graham, N. M., and the VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS., 16, 579- 588 (2002)
DOI
ScienceOn
|
164 |
Little, S. J., Holte, S., Routy, J.-P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., Kilby, M., Wang, L., Whitcomb, J. M., Hellmann, N. S., and Richman, D. D., Antiretroviral-Drug Resistance among Patients Recently Infected with HIV. N. Engl. J. Med., 347, 385-394 (2002a)
DOI
ScienceOn
|
165 |
Meynard, J. L., Vray, M., Morand-Joubert, L., Race, E., Descamps, D., Peytavin, G., Matheron, S., Lamotte, C., Guiramand, S., Costagliola, D., Brun-Vezinet, F., Clavel, F., Girard, P. M., and the Narval Trial Group. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS., 16, 727-736 (2002)
DOI
ScienceOn
|
166 |
MMWR. Incidence of Acute Hepatitis B-United States, 1990- 2002. MMWR., 51, 1252-1254 (2004)
|
167 |
Steel, H. M., Special presentation on aplaviroc-related hepatotoxicity. Program and abstracts of the European AIDS Clinical Society 10th European AIDS Conference; November 17-20, Dublin, Ireland (2005)
|
168 |
Gerstoft, J., Dragsted, U. B., and Cahn, P., Final analysis of a randomized trial to evaluate safety and efficacy of indinavir/ ritonavir versus saquinavir/ritonavir in adult HIV-1 infection: the MAXCmin1 trial [abstract P29]. 6th International Congress on Drug Therapy in HIV Infection (Glasgow). London: Lippincott Williams & Wilkins, (2002)
|
169 |
Havlir, D. V. and O'Marro, S. D., Atazanavir: New Option for Treatment of HIV Infection. Clin. Infect. Dis., 38, 1599-1604 (2004)
DOI
ScienceOn
|
170 |
Jourdain, G., Ngo-Giang-Huong, N., LeCour, S., Bowonwatanuwong, C., Kantipong, P., Leechanachai, P., Ariyadej, S., Leenasirimakul, P., Hammer, S., Lallemant, M., and the Perinatal HIV Prevention Trial Group. Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy. N. Engl. J. Med., 351, 229-240 (2004)
DOI
ScienceOn
|
171 |
Thea, D. M, Steketee, R. W., Pliner, V., Bornschlegel, K., Brown, T., Orloff, S., Matheson, P. B., Abrams, E. J., Bamji, M., Lambert, G., Schoenbaum, E. A., Thomas, P. A., Heagarty, M., and Kalish, M. L., The effect of maternal viral load on the risk of perinatal transmission of HIV-1. AIDS., 11, 437-44 (1997)
DOI
ScienceOn
|
172 |
Lafeuillade, A., Hittinger, G., and Chapadaud, S., Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet., 357, 280-281 (2001)
DOI
ScienceOn
|
173 |
Salmon-Céron, D., Chauvelot-Moachon, L., Abad, S., Silbermann, B., and Sogni, P., Mitochondrial toxic effects and ribavirin. Lancet., 357, 1803-1804 (2001)
DOI
ScienceOn
|
174 |
Squires, K., Lazzarin, A., Gatell, J. M., Powderly, W. G., Pokrovskiy, V., Delfraissy, J. F., Jemsek, J., Rivero, A., Rozenbaum, W., Schrader, S., Sension, M., Vibhagool, A., Thiry, A., and Giordano, M., Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. AIDS., 36, 1011-1019 (2004)
DOI
ScienceOn
|
175 |
Molto, J., Ruiz, L., Romeu, J., Martinez-Picado, J., Negredo, E., Tural, C., Sirera, G., and Clotet, B., Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. AIDS Res. & Hum. Retrovir., 20, 1283-1288 (2004)
DOI
ScienceOn
|
176 |
Acosta, E. P., Page, L. M., and Fletcher, C. V., Clinical pharmacokinetics of zidovudine. Clin. Pharmacokinet., 30, 251-262 (1996)
DOI
ScienceOn
|
177 |
Bergshoeff, A., Burger, D., Verweij, C., Farrelly, L., Flynn, J., Le Prevost, M., Walker, S., Novelli, V., Lyall, H., Khoo, S., and Gibb, D., for the PENTA-13 Study Group. Plasma pharmacokinetics of once-versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1- infected children (PENTA-13). Antivir. Ther., 10, 239-246 (2005)
|
178 |
CDC. Treating Opportunistic Infections among HIV-infected adults and adolescents. Recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR, 53, RR-15 (2004)
|
179 |
Levine, S., Hernandez, D., Yamanaka, G., Zhang, S., Rose, R., Weinheimer, S., and Colonno, R. J., Efficacies of Entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents. Chemother., 46, 2525-2532 (2002)
DOI
ScienceOn
|
180 |
Marrone, A., Zampino, R., Karayannis, P., Cirillo, G., Cesaro, G., Guerrera, B., Ricciotti, R., del Giudice, E. M., Utili, R., Adinolfi, L. E., and Ruggiero, G., Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis. Aliment. Pharm. Therap., 22, 707-714 (2005)
DOI
ScienceOn
|
181 |
Piscitelli, S. C. and Gallicano, K. D., Interactions among drugs for HIV and opportunistic infections. N. Engl. J. Med., 344, 984-996 (2001)
DOI
ScienceOn
|
182 |
Pollard, R. B., Robinson, P., and Dransfield, K., Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin. Therap., 20, 1071-1092 (1998)
DOI
ScienceOn
|
183 |
Ioannidis, J. P. A., Abrams, E. J., Ammann, A., Bulterys, M., Goedert, J. J., Gray, L., Korber, B. T., Mayaux, M. J., Mofenson, L. M., Newell, M. L., Shapiro, D. E., Teglas, J. P., and Wilfert, C. M., Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J. Infect. Dis., 183, 539-545 (2001)
DOI
ScienceOn
|
184 |
Colfax, G. N., Buchbinder, S. P., Corneliss, P. G., Vittinghoff, E., Mayer, K., and Celum, C., Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS., 16, 1529-1535 (2002)
DOI
ScienceOn
|
185 |
Friedland, G. H., Pollard, R., Griffith, B., Hughes, M., Morse, G., Bassett, R., Freimuth, W., Demeter, L., Connick, E., Nevin, T., Hirsch, M., and Fischl, M., Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3. J. AIDS., 21, 281-292 (1999)
DOI
ScienceOn
|
186 |
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., Chodakewitz, J. A., and Fischl, M. A., A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med., 337, 725-733 (1997)
DOI
ScienceOn
|
187 |
Kearney, B. P., Mittan, A., Sayre, J., Flaherty, J. F., Zhong, L., Toole, J. J., and Cheng, A. K., Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ ritonavir. Abstract A-1617. ICAAC September 2003 Chicago Ill
|
188 |
Kilby, J. M., Inhibitors of HIV attachment and fusion. P. 252-262. In Dolin R, Masur H, and Saag MS (ed),AIDS Therapy. Churchill Livingstone, Philadelphia. (1999)
|
189 |
Kohlbrenner, V. M., Development of a tipranavir mutation score: analysis of protease mutations associated with phenotypic drug susceptibility and antiviral response in Phase II clinical trials. XIII International HIV Drug Resistance Workshop. Tenerife, Spain. (2004)
|
190 |
Montaner, J. S. G., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., Wainberg, M. A., Smith, D., Robinson, P., Hall, D., Myers, M., and Lange, J. M. A., A randomized, doubleblind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. JAMA., 279, 930- 937 (1998)
DOI
ScienceOn
|
191 |
Troisi, C. L., Hollinger, F. B., Hoots, W. K., Contant, C., Gill, J., Ragni, M., Parmley, R., Sexauer, C., Gomperts, E., and Buchanan, G., A multicenter study of viral hepatitis in a United States hemophilic population. Blood, 81, 412-418 (1993)
|
192 |
Zhang, Y. M., Imamichi, H., Imamichi, T., Lane, H. C., Falloon, J., Vasudevachari, M. B., and Salzman, N. P., Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol., 71, 6662-6670 (1997)
|
193 |
UNAIDS/WHO. Report on the Global HIV/AIDS Epidemic. January (2006)
|
194 |
Bonnet, F., Bonarek, M., Morlat, P., Mercie, P., Dupon, M., Gemain, M. C., Malvy, D., Bernard, N., Pellegrin, J. L., and Beylot, J., Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin. Infect. Dis., 36, 1324- 1328 (2003)
DOI
ScienceOn
|
195 |
D'Aquila, R. M., Hughes, M. D., Johnson, V. A., Fischl, M. A., Sommadossi, J. P., Liou, S. -H., Timpone, J., Myers, M., Basgoz, N., Niu, M., and Hirsch, M. S., Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann. Intern. Med., 124, 1019- 1030 (1996)
DOI
ScienceOn
|
196 |
Dickover, R. E., Garratty, E. M., Herman, S. A., Sim, M. S., Plaeger, S., Boyer, P. J., Keller, M., Deveikis, A., Stiehm, E. R., and Bryson, Y. J., Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA., 275, 599-605 (1996)
DOI
|
197 |
Garcia, P. M., Kalish, L. A., Pitt, J., Minkoff, H., Quinn, T. C., Burchett, S. K., Kornegay, J., Jackson, B., Moye, J., Hanson, C., Zorrilla, C., and Lew, J. F., Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N. Engl. J .Med., 341, 394-402 (1999)
DOI
ScienceOn
|
198 |
Hughes, M. D., Johnson, V. A., Hirsch, M. S., Bremer, J. W., Elbeik T., Erice, A., Kuritzkes, D. R., Scott, W. A., Spector, S. A., Basgoz, N., Fischl, M. A., and D'Aquila, R. T., Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann. Intern. Med., 126, 929-938 (1997)
DOI
ScienceOn
|
199 |
Lee, W. M., Medical Progress: Hepatitis B Virus Infection. N. Engl. J. Med., 337, 1733-1745 (1997)
DOI
ScienceOn
|
200 |
Monga, H. K., Rodriguez-Barradas, M. C., Breaux, K., Khattak, K., Troisi, C. L., Velez, M., and Yoffe, B., Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin. Infect. Dis., 33, 240-247 (2001)
DOI
ScienceOn
|
201 |
Cooper, C. L., van Heeswijk, R. P. G., Gallicano, K., and Cameron, D. W., A Review of Low-Dose Ritonavir in Protease Inhibitor Combination Therapy. Clin. Infect. Dis., 36, 1585-1592 (2003)
DOI
ScienceOn
|
202 |
Benhamou, Y., Bochet, M., Thibault, V., Di Martino, V., Caumes, E., Bricaire, F., Opolon, P., Katlama, C., and Poynard T., Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology, 30, 1302-1306 (1999)
DOI
|
203 |
Dore, G. J., Cooper, D. A., Barrett, C., Goh, L. E., Thakrar, B., and Atkins, M., Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J. Infect. Dis., 180, 607- 613 (1999)
DOI
ScienceOn
|
204 |
Hirsch, M. S., Brun-Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D'Aquila, R. T., Demeter, L. M., Hammer, S. M., Johnson, V. A., Loveday, C., Mellors, J. W., Jacobsen, D. M., and Richman, D. D., Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society- USA Panel. Clin. Infect. Dis., 37, 113-128 (2003)
DOI
ScienceOn
|
205 |
Ledergerber, B., Egger, M., Erard, V., Weber, R., Hirschel, B., Furrer, H., Battegay, M., Vernazza, P., Bernasconi, E., Opravil, M., Kaufmann, D., Sudre, P., Francioli, P., and Telenti, A., AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. JAMA., 282, 2220-2226 (1999)
DOI
ScienceOn
|
206 |
Morsica, G., De Bona, A., Uberti, C., Sitia, G., Finazzi, R., and Lazzarin, A., Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. AIDS., 14, 1656-1658 (2000)
DOI
ScienceOn
|
207 |
Clevenbergh, P., Corcostegui, M., Gerard, D., Hieronimus, S., Mondain, V., Chichmanian, R. M., Sadoul, J. L., and Dellamonica, P., Iatrogenic Cushing's syndrome in an HIVinfected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen. J. Infection., 44, 194-195 (2002)
DOI
ScienceOn
|
208 |
de Franchis, R., Hadengue, A., Lau, G., Lavanchy, D., Lok, A., McIntyre, N., Mele, A., Paumgartner, G., Pietrangelo, A., Rodes, J., Rosenberg, W., Valla, D., and the EASL Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J. Hepatol., 39 (Suppl 1), S3-25 (2003)
|
209 |
Gallant, J. E., Staszewski, S., Pozniak, A. L., DeJesus, E., Suleiman, J. M., Miller, M. D., Coakley, D. F., Lu, B., Toole, J. J., and Cheng, A. K., 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA., 292, 191-201 (2004)
DOI
ScienceOn
|
210 |
American College of Obstetricians and Gynecologists Committee Opinion. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Number 234. Washington DC: The American College of Obstetricians and Gynecologists, May (2000)
|
211 |
Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., and Pau, A. K., Guidelines for Using Antiretroviral Agents Among HIVInfected Adults and Adolescents. MMWR., 51(RR7), 1-64 (2002)
|
212 |
El-Sadr, W. and Neaton, J., Episodic CD4-guided use of antiretroviral therapy is inferior to continuous therapy: results of the SMART study. Abstract 106LB Conference on Retroviruses and Opportunistic Infections. Denver, CO. U.S.A., (2006)
|
213 |
Pramoolsinsup, C., Management of viral hepatitis B. J. Gastroen. Hepatol., 17, S125-S145 (2002)
DOI
|
214 |
Garcia-Samaniego, J., Rodriguez, M., Berenguer, J., Rodriguez- Rosado, R., Carbo, J., Asensi, V., and Soriano, V., Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am. J. Gastroenterol., 96, 179-183 (2001)
DOI
|
215 |
Miller, V., Staszewski, S., Boucher, C. A., and Phair, J. P., Clinical experience with non-nucleoside reverse transcriptase inhibitors. AIDS., 11, (suppl A), S157-S164 (1997)
DOI
ScienceOn
|
216 |
Perry, C. M. and Faulds, D., Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs, 53, 657-680 (1997)
DOI
ScienceOn
|
217 |
Saag, M. S., Holodniy, M., Kuritzkes, D. R., O'Brien, W. A., Coobs, R., Poscher, M. E., Jacobsen, D. M., Shaw, G. M., Richman, D. D., and Volberding, P. A., HIV viral load markers in clinical practice. Nature. Med., 6, 625-629 (1996)
|
218 |
Saksela, K., Stevens, C. E., Rubinstein, P., Taylor, P. E., and Baltimore, D., HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann. Intern. Med., 123, 641-648 (1995)
DOI
ScienceOn
|
219 |
Tedaldi, E. M., Baker, R. K., Moorman, A. C., Alzola, C. F., Furhrer, J., McCabe, R. E., Wood, K. C., and Holmberg, S. D., HIV Outpatient Study (HOPS) Investigators. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin. Infect. Dis., 36, 363- 367 (2003)
DOI
ScienceOn
|
220 |
Vento, S., Di Perri, G., Cruciani, M., Garofano, T., Concia, E., and Bassetti, D., Rapid decline of CD4+ cells after interferon treatment in HIV-1 infection. Lancet., 341, 958–959 (1993)
DOI
|
221 |
Quinn, T. C., Wawer, M. J., Sewankambo, N., Serwadda, D., Li C., Wabwire-Mangen, F., Meehan, M. O., Lutalo, T., and Gray R. H., Viral load and heterosexual transmission of immunodeficiency virus type 1. N. Engl. J. Med., 342, 921- 929 (2000)
DOI
ScienceOn
|
222 |
Di Martino, V., Rufat, P., Boyer, N., Renard, P., Degos, F., Martinot-Peignoux, M., Matheron, S., Le Moing,V., Vachon, F., Degott, C., Valla, D., and Marcellin, P. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology, 34, 1193-1199 (2001)
DOI
ScienceOn
|
223 |
Kilby, J. M., Sfakianos, G., Gizzi, N., Siemon-Hryczyk, P., Ehrensing, E., Oo, C., Buss, N., and Saag, M. S. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother., 44, 2672-2678 (2000)
DOI
|
224 |
Lallemant, M., Jourdain, G., LeCoeur, S., Mary, J. Y., Ngo- Giang-Huong, N., Koetsawang, S., Kanshana, S., McIntosh, K., Thaineua, V., and the Perinatal HIV Prevention Trial (Thailand) Investigators. Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother-to-Child Transmission of HIV-1 in Thailand. N. Engl. J. Med., 351, 217-228 (2004)
DOI
ScienceOn
|
225 |
Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., Johnson, D., Lalonde, R., Japour, A., Brun, S., and Sun, E., M98-863 Study Team. Lopinavirritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med., 346, 2039-2046 (2002)
DOI
ScienceOn
|
226 |
Youle, M., Mocroft, A., and Johnson, M., Lipid profiles in patients on ritonavir/indinavir containing salvage regimens [abstract 24]. Antivir. Ther., 4 (Suppl 2), 22 (1999)
|
227 |
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L. Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., and Yu, J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 347, 975-982 (2002)
DOI
ScienceOn
|
228 |
Bonacini, M., Lin, H. J., and Hollinger, F. B., Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J. AIDS., 26, 340-344 (2001)
DOI
|
229 |
Bossi, P., Colin, D., Bricaire, F., and Caumes, E., Hypersensitivity syndrome associated with efavirenz therapy. Clin. Infect. Dis., 30, 227-228 (2000)
DOI
ScienceOn
|
230 |
Fish, D. E., Hay, A., Waters, J. A., McGarvey, M. J., Main, J., and Thomas, H. C., Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J. Clin. Pathol., 43, 203-205 (1990)
DOI
|
231 |
Gallant, J. E. and Deresinski, S., Tenofovir disoproxil fumarate. Clin. Infect. Dis., 37, 944-950 (2003)
DOI
ScienceOn
|
232 |
Hewitt, R. G., Abacavir hypersensitivity reaction. Clin. Infect. Dis., 34, 1137-1142 (2002)
DOI
ScienceOn
|
233 |
The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. A meta-analysis of 15 prospective cohort studies. N. Engl. J. Med., 340, 977-987 (1999)
DOI
ScienceOn
|
234 |
Marcelin, A. G., Delaugerre, C., Wirden, M., Viegas, P., Simon, A., Katlama, C., and Calvez, V., Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J. Med. Virol., 72, 162-165 (2004)
DOI
ScienceOn
|
235 |
Mellors, J. W., Rinaldo, C. R., Gupta, P., White, R. M., Todd, J. A. and Kingsley, L. A., Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 272, 1167-1170 (1996)
DOI
ScienceOn
|
236 |
Mofenson, L. M., Lambert, J.S., Stiehm, E.R., Bethel, J., Meyer, W. A., Whitehouse, J., Moye J., Reichelderfer, P., Harris, D. R., Fowler, M. G., Mathieson, B. J., and Nemo, G. J., Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N. Engl. J. Med., 341, 385-393 (1999)
DOI
ScienceOn
|
237 |
Fargioin, S., Fracanzani, A. L., and Valenti, L., Treatment Choices for people infected with HCV. J. Antimicrob. Chemother., 53, 708-712 (2004)
DOI
ScienceOn
|
238 |
Roberts, J. D., Bebenek, K., and Kunkel, T. A., The accuracy of reverse transcriptase from HIV-1. Science, 242, 1171-1173 (1998)
DOI
|
239 |
Antoniou, T. and Tseng, A. L., Interactions between recreational drugs and antiretroviral agents. Ann. Pharmacother., 36, 1598-1613 (2002)
DOI
ScienceOn
|
240 |
Di Martino, V., Thevenot, T., Boyer, N., Degos, F., and Marcellin, P., Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. Hepatology, 31, 1030-1031 (2000)
|
241 |
Miller, V., Mocroft, A., Reiss, P., Katlama, C., Papadopoulos, A. I., Katzenstein, T., Van Lunzen, J., Antunes, F., Phillips, A. N., and Lundgren, J. D., Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann. Intern. Med.,130, 570-577 (1999)
DOI
ScienceOn
|
242 |
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A., Emini, E. A., and Chodakewitz, J. A., Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med., 337, 734-739 (1997)
DOI
ScienceOn
|
243 |
Little, S. J., Daar, E. S., Holte, S., Frost, S., Routy, J. P., Markowitz, M., Collier, A. C., Margolick, J. B., Koup, R. A., Conway, B., Connick, E., Kilby, M., Wrin, T., Petropoulos, C. J., Hellmann, N. S., and Richman, D. D., Persistence of transmitted drug resistance among subjects with primary HIV infection not receiving antiretroviral therapy. In: 9th Conference on Retroviruses and Opportunistic Infections. Abstract 95. (2002b)
|
244 |
McMahon, B. J., Epidemiology and natural history of hepatitis B. Sem. Liver. Disease., 1 (25 Suppl), 3-8 (2005)
|
245 |
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., and Holmberg, S. D., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med., 338, 853-60 (1998)
DOI
ScienceOn
|
246 |
Soriano, V., Puoti, M., Sulkowski, M., Mauss, S., Cacoub, P., Cargnel, A., Dieterich, D., Hatzakis, A., and Rockstroh, J., Care of patients with hepatitis C and HIV co-infection. Updated recommendations from the HIV-HCV International Panel. AIDS., 18, 1-12 (2004)
DOI
ScienceOn
|
247 |
Colin, J. F., Cazals-Hatem, D., Loriot, M. A., Martinot-Peignoux, M., Pham, B. N., Auperin, A., Degott, C., Benhamou, J. P., Erlinger, S., Valla, D., and Marcellin P. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology, 29, 1306-1310 (1999)
DOI
ScienceOn
|
248 |
Quaranta, J. F., Delaney, S. R., Alleman, S., Cassuto, J. P., Dellamonica, P., and Allain, J. P., Prevalence of antibody to hepatitis C virus (HCV) in HIV-1-infected patients (nice SEROCO cohort). J. Med. Virol., 42, 29-32 (1994)
DOI
ScienceOn
|
249 |
van Leth, F., Phanuphak, P., Ruxrungtham, K., Baraldi, E., Miller, S., Gazzard, B., Cahn, P., Lalloo, U. G., van der Westhuizen, I. P., Malan, D. R., Johnson, M. A., Santos, B. R., Mulcahy, F., Wood, R., Levi, G. C., Reboredo, G., Squires, K., Cassetti, I., Petit, D., Raffi, F., Katlama, C., Murphy, R. L., Horban, A., Dam, J. P., Hassink, E., van Leeuwen, R., Robinson, P., Wit, F. W., and Lange, J. M. 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet., 363, 1253-1263 (2004)
DOI
ScienceOn
|
250 |
Watts, D. H., Management of Human Immunodeficiency Virus Infection in Pregnancy. N. Engl. J. Med., 346, 1879-1891 (2002)
DOI
ScienceOn
|
251 |
Esnouf, R. M., Ren, J., Hopkins, A. L., Ross, C. K., Jones, E. Y., Stammers, D. K., and Stuart, D. I., Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. P. Natl. Acad. Sci. U.S.A., 94, 3984-3989 (1997)
|
252 |
Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S., Piliero, P. J.. Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J. Jr., Chung, J., DeMasi, R., Donatacci, L., Drobnes, C., Delehanty, J., and Salgo, M., TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med., 348, 2175-2185 (2003)
DOI
ScienceOn
|
253 |
Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D. D., Richman, D. D., and Siliciano, R. F., Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 278, 1295-300 (1997)
DOI
ScienceOn
|
254 |
Gao, H. Q., Boyer, P. L., Sarafianos, S. G., Arnold, E., and Hughes, S. H., The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J. Molec. Biol., 300, 403-418 (2000)
DOI
ScienceOn
|
255 |
Gulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K. E., Meyer, W. A. 3rd., Acosta, E. P., Schackman. B. R., Pilcher. C. D., Murphy, R. L., Maher, W. E., Witt, M. D., Reichman, R. C., Snyder, S., Klingman, K. L., and Kuritzkes, D. R., AIDS Clinical Trials Group Study A5095 Team. Triplenucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med., 350, 1850-1861 (2004)
DOI
ScienceOn
|
256 |
Lawrence, J., Mayers, D. L., Hullsiek, K. H., Collins, G., Abrams, D. I., Reisler, R. B., Crane, L. R., Schmetter, B. S., Dionne, T. J., Saldanha, J. M., Jones, M. C., and Baxter, J. D., 064 Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N. Engl. J. Med., 349, 837-846 (2003)
DOI
ScienceOn
|
257 |
Panlilio, A. L., Cardo, D. M. Grohskopf, L. A., Heneine, W., and Ross, C. S., Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis. MMWR., 54 (RR09), 1-17 (2005)
|
258 |
Gathe, J. C. Jr., Ive, P., Wood, R., Schurmann, D., Bellos, N. C., DeJesus, E., Gladysz, A., Garris, C., and Yeo, J., SOLO: 48- week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1- infected patients. AIDS., 18, 1529-1537 (2004)
DOI
ScienceOn
|
259 |
Alberti, A., Clumeck, N., Collins, S., Gerlich, W., Lundgren, J., Palu, G., Reiss, P., Thiebaut, R., Weiland, O., Yazdanpanah, Y., and Zeuzem, S., Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J. Hepatol., 42, 615-624 (2005)
DOI
ScienceOn
|
260 |
Croom, K. F. and Keam, S. J., Tipranavir, A ritonavir boosted protease inhibitor. Drug, 65, 1669-1677 (2005)
DOI
ScienceOn
|
261 |
Hurst, M. and Noble, S., Stavudine: an update of its use in the treatment of HIV infection. Drugs, 58, 919-949 (1998)
DOI
ScienceOn
|
262 |
Tural, C., Ruiz, L., Holtzer, C., Schapiro, J., Viciana, P., Gonzalez, J., Domingo, P., Boucher, C., Rey-Joly, C., and Clotet, B., for the Havana Study Group. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS., 16, 209-218 (2002)
DOI
ScienceOn
|
263 |
Minkoff, H. and Augenbraun, M., Antiretroviral therapy for pregnant women. Am. J. Obstet. Gynecol., 176, 478-489 (1997)
DOI
ScienceOn
|
264 |
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., Manion, D. J., and Ruiz, N. M., Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N. Engl. J. Med., 341, 1865-1873 (1999)
DOI
ScienceOn
|
265 |
Thio, C. L., Seaberg, E. C., Skolasky, R., Phair, J., Visscher, B., Munoz, A., and Thomas, D. L., for the Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet., 360, 1921-1926 (2002)
DOI
ScienceOn
|
266 |
van Heeswijk, R. P., Veldkamp, A. I., Hoetelmans, R. M., Mulder, J. W., Schreij, G., Hsu, A., Lange, J. M., Beijnen, J. H., and Meenhorst, P. L., The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1- infected individuals. AIDS., 13, F95-99 (1999)
DOI
ScienceOn
|